| 1 |
33856277 | Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. | 2021 Sep |
1 |
| 2 |
33989279 | Lenalidomide in DLBCL: are we past the cell of origin? | 2021 May |
1 |
| 3 |
30926391 | Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. | 2019 Jun |
1 |
| 4 |
30701929 | Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature. | 2018 Aug 17 |
1 |
| 5 |
28592763 | Malignant lymphoma: pathophysiology and current therapy. | 2017 |
1 |
| 6 |
27089170 | ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. | 2016 Jul |
1 |
| 7 |
22698399 | Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. | 2012 Jun 12 |
3 |